Eurocine Vaccines AB announces the completion of knowledge transfer and preparations for the development of the manufacturing process for the company´s chlamydia vaccine candidate. The process development activities initiated at Biovian according to schedule, are …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
The article discusses the challenges small and mid-sized companies are facing when taking AAV vector-based innovations from the laboratory bench to the clinic. While in-house manufacturing may be an option for some companies, partnering with a …
Adenoviruses are among the most attractive Viral Vectors for gene therapy because of their well-defined biology and characteristics. They have a high packaging capacity and can accommodate large transgene inserts of sizes up to ~8 kb. Adenovirus vectors also have high transduction efficiency and they can infect both dividing and non-dividing cells in a broad range of cell and tissue …
Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
Eurocine Vaccines AB has selected Biovian Oy, Turku, Finland, as the contract developer for the Company’s vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract developer and manufacturer with its own GMP facility, …
We are humbled and grateful to inform that Biovian received a Net Promoter Score, NPS of 72 in the client satisfaction survey. Based on Bain & Co, the source of the NPS system, this score …
We are pleased to announce that Biovian has obtained the Accreditation Certificate of Foreign Drug Manufacturer from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Application category is Biological Products and Number of Accreditation AG22200020. …
We are pleased to let you know that Magnus Gustafsson from Biovian will speak about New Biologicals at “New Horizons in Biologics & Bioprocessing digital event”, on December 17th at 8:45 (CET). TALK: Manufacture and …